A Phase 2, Single-Center, Randomized, Double-Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of SkQ1 Ophthalmic Solution in the Environment and During Challenge in the CAE(SM) Model for the Treatment of Dry Eye Syndrome

Trial Profile

A Phase 2, Single-Center, Randomized, Double-Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of SkQ1 Ophthalmic Solution in the Environment and During Challenge in the CAE(SM) Model for the Treatment of Dry Eye Syndrome

Completed
Phase of Trial: Phase II

Latest Information Update: 05 Jan 2016

At a glance

  • Drugs Plastoquinonyl-decyl-triphenylphosphonium (Primary)
  • Indications Dry eyes; Keratoconjunctivitis sicca
  • Focus Therapeutic Use
  • Sponsors Mitotech
  • Most Recent Events

    • 05 Jan 2016 Results published in the Advances in Therapy
    • 23 Apr 2015 According to Mitotech media release, the company had a successful "End of Phase II" meeting with the FDA in January 2015 confirming the remaining requirements for the clinical development plan.
    • 23 Apr 2015 According to Mitotech media release, the poster with data from this trial accepted for presentation at the 2015 ARVO Annual Meeting held May 3-7, 2015, in Denver, Colorado.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top